Metabolomics company Metabolon just raised about $5 million in equity from four investors, according to a recent regulatory filing. The metabolomics company plays in the precision medicine space, providing phenotyping tech that can, say, determine how an individual reacts to a drug.
There were whispers about a year ago that Metabolon was readying itself for IPO, but that has yet to happen. The Wall Street Journal wrote at the time:
The company generated about $25 million in revenue last year, people familiar with the IPO planning said.
It is backed by roughly $50 million in private funding, including from Aurora Funds Inc., Fletcher Spaght Ventures LP, Syngenta Ventures, Sevin Rosen Funds, Harris & Harris Group Inc. and Keating Capital Inc.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This new round is the latest Metabolon has raised since 2013. The company also made some waves a year ago when it announced it had teamed up with J. Craig Venter’s well-funded genomics company meant to elongate human life – Human Longevity Inc.
Calls to Metabolon to learn what the new funding will be used for have yet to be returned; stay tuned for more.